Scholar RockSRRK
About: Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
Employees: 150
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1.29% more ownership
Funds ownership: 106.78% [Q2] → 108.07% (+1.29%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 54
2% less capital invested
Capital invested by funds: $709M [Q2] → $693M (-$16M) [Q3]
3% less funds holding
Funds holding: 164 [Q2] → 159 (-5) [Q3]
17% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 30
27% less call options, than puts
Call options by funds: $4.71M | Put options by funds: $6.43M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
HC Wainwright & Co. Andres Maldonado 29% 1-year accuracy 13 / 45 met price target | 12%upside $50 | Buy Maintained | 26 Nov 2024 |
Wedbush David Nierengarten 38% 1-year accuracy 49 / 128 met price target | 5%upside $47 | Outperform Maintained | 25 Nov 2024 |
Truist Securities Srikripa Devarakonda 33% 1-year accuracy 10 / 30 met price target | 0%upside $45 | Buy Maintained | 25 Nov 2024 |
Piper Sandler Allison Bratzel 82% 1-year accuracy 9 / 11 met price target | 6%downside $42 | Overweight Maintained | 15 Oct 2024 |
JP Morgan Tessa Romero 22% 1-year accuracy 4 / 18 met price target | 31%downside $31 | Overweight Maintained | 14 Oct 2024 |